In conclusion, we find that FASN gene body methylation is significantly inversely correlated with FASN expression across multiple primary and metastatic prostate cancer cohorts, and we demonstrate that prostate tumors from carriers of the germline HOXB13 G84E mutation show increased FASN expression, consistent with recent evidence of epigenetic FASN regulation in vitro. The gene discussed is FASN; the disease is metastatic prostate carcinoma.